PKP-028 Plasma concentration of a standard dose of vancomycin and relationship with body mass index
PurposeThe objective of this study was to evaluate a standard starting dose of vancomycin and a possible relationship between body mass index (BMI) and plasma levels (therapeutic range 10–15 µg/mL).Material and methodsRetrospective study of samples collected in a tertiary hospital of 413 beds, over...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A191-A191 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A191 |
---|---|
container_issue | Suppl 1 |
container_start_page | A191 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 23 |
creator | Llorca, A Marti Mateos, A Andújar Iranzo, E Garcia Vozmediano, R Gutiérrez Monsalve, A García Ruiz, A Navarro |
description | PurposeThe objective of this study was to evaluate a standard starting dose of vancomycin and a possible relationship between body mass index (BMI) and plasma levels (therapeutic range 10–15 µg/mL).Material and methodsRetrospective study of samples collected in a tertiary hospital of 413 beds, over a period of 3 years (2012–2014), in patients who were prescribed a standard initial dose of vancomycin 1 g/12 h.Data collected were: weight, height, gender, age, creatinine plasma levels and vancomycin plasma levels. The collected data were grouped according to BMI (18.5–25=normal weight, 25–30=overweight and >30=obesity) and plasma concentrations of vancomycin. Exclusion criteria were: samples from patients with renal insufficiency (creatinine >1.2 mg/dL) and patients with an initial dose of vancomycin different from the standard dose.The relationship between plasma levels of vancomycin and BMI was assessed by ANOVA statistical analysis.Results114 determinations of plasma levels of vancomycin from different patients were reviewed; 51 normal weight patients, 45 overweight patients and 18 obese patients, with a mean age of 61.27 ± 18.49, 68.46 ± 13.07 and 66.27 ± 13.47 years, respectively.In the normal weight group, 74.5% were men and 25.5% were women; in overweight group, 73.3% were men and 26.7% were women; and in obesity group, 66.6% were men and 33.3% were women.Mean (SD) plasma levels of vancomycin in the normal weight group were 13.98 ± 10.61 µg/mL, in the overweight group 13.77 ± 8.32 µg/mL and in the obese group 10.7 ± 4.67 µg/mL.In the statistical study, we obtained a value distribution F of 1.1669, less than 3.09, a value that should be overcome to have statistical significance (95%).ConclusionThe standard starting dose of 1 g/12 h reaches the therapeutic range in most patients. There was no statistically significant relationship between BMI and mean plasma levels of vancomycin in our study, possibly because of the small sample size.No conflict of interest. |
doi_str_mv | 10.1136/ejhpharm-2016-000875.431 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552751919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552751919</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1009-e04d2e63ccf9b06e151702d24029f200f277a2309c444b6b06805012f26b8f1e3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EElXpP1hinTJ-x0tU8RKV6ALWlpM4SqrGDnYKdMeGH-VLSCmwZDWjmaN7pYMQJjAnhMkLt276xsYuo0BkBgC5EnPOyBGaUOAq01ry479dyFM0S6ktQDCWa870BLnV_SoDmn--f6w2NnUWl8GXzg_RDm3wONTY4jRYX9lY4Soktz-9WF-Gble2Ho8fHN3mm05N2-PXdmhwEaod7mxKuPWVeztDJ7XdJDf7mVP0dH31uLjNlg83d4vLZVYQAJ054BV1kpVlrQuQjgiigFaUA9U1BaipUpYy0CXnvJAjkoMAQmsqi7wmjk3R-SG3j-F569Jg1mEb_VhpqBBUCaKJ_o8iKudCaKXZSLEDVXRr08e2s3FnCJi9ePMr3uzFm4N4M4pnX2Lsd24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784559793</pqid></control><display><type>article</type><title>PKP-028 Plasma concentration of a standard dose of vancomycin and relationship with body mass index</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Llorca, A Marti ; Mateos, A Andújar ; Iranzo, E Garcia ; Vozmediano, R Gutiérrez ; Monsalve, A García ; Ruiz, A Navarro</creator><creatorcontrib>Llorca, A Marti ; Mateos, A Andújar ; Iranzo, E Garcia ; Vozmediano, R Gutiérrez ; Monsalve, A García ; Ruiz, A Navarro</creatorcontrib><description>PurposeThe objective of this study was to evaluate a standard starting dose of vancomycin and a possible relationship between body mass index (BMI) and plasma levels (therapeutic range 10–15 µg/mL).Material and methodsRetrospective study of samples collected in a tertiary hospital of 413 beds, over a period of 3 years (2012–2014), in patients who were prescribed a standard initial dose of vancomycin 1 g/12 h.Data collected were: weight, height, gender, age, creatinine plasma levels and vancomycin plasma levels. The collected data were grouped according to BMI (18.5–25=normal weight, 25–30=overweight and >30=obesity) and plasma concentrations of vancomycin. Exclusion criteria were: samples from patients with renal insufficiency (creatinine >1.2 mg/dL) and patients with an initial dose of vancomycin different from the standard dose.The relationship between plasma levels of vancomycin and BMI was assessed by ANOVA statistical analysis.Results114 determinations of plasma levels of vancomycin from different patients were reviewed; 51 normal weight patients, 45 overweight patients and 18 obese patients, with a mean age of 61.27 ± 18.49, 68.46 ± 13.07 and 66.27 ± 13.47 years, respectively.In the normal weight group, 74.5% were men and 25.5% were women; in overweight group, 73.3% were men and 26.7% were women; and in obesity group, 66.6% were men and 33.3% were women.Mean (SD) plasma levels of vancomycin in the normal weight group were 13.98 ± 10.61 µg/mL, in the overweight group 13.77 ± 8.32 µg/mL and in the obese group 10.7 ± 4.67 µg/mL.In the statistical study, we obtained a value distribution F of 1.1669, less than 3.09, a value that should be overcome to have statistical significance (95%).ConclusionThe standard starting dose of 1 g/12 h reaches the therapeutic range in most patients. There was no statistically significant relationship between BMI and mean plasma levels of vancomycin in our study, possibly because of the small sample size.No conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2016-000875.431</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Antibiotics ; Body mass index ; Creatinine ; Obesity ; Overweight ; Plasma</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A191-A191</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2016 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Llorca, A Marti</creatorcontrib><creatorcontrib>Mateos, A Andújar</creatorcontrib><creatorcontrib>Iranzo, E Garcia</creatorcontrib><creatorcontrib>Vozmediano, R Gutiérrez</creatorcontrib><creatorcontrib>Monsalve, A García</creatorcontrib><creatorcontrib>Ruiz, A Navarro</creatorcontrib><title>PKP-028 Plasma concentration of a standard dose of vancomycin and relationship with body mass index</title><title>European journal of hospital pharmacy. Science and practice</title><description>PurposeThe objective of this study was to evaluate a standard starting dose of vancomycin and a possible relationship between body mass index (BMI) and plasma levels (therapeutic range 10–15 µg/mL).Material and methodsRetrospective study of samples collected in a tertiary hospital of 413 beds, over a period of 3 years (2012–2014), in patients who were prescribed a standard initial dose of vancomycin 1 g/12 h.Data collected were: weight, height, gender, age, creatinine plasma levels and vancomycin plasma levels. The collected data were grouped according to BMI (18.5–25=normal weight, 25–30=overweight and >30=obesity) and plasma concentrations of vancomycin. Exclusion criteria were: samples from patients with renal insufficiency (creatinine >1.2 mg/dL) and patients with an initial dose of vancomycin different from the standard dose.The relationship between plasma levels of vancomycin and BMI was assessed by ANOVA statistical analysis.Results114 determinations of plasma levels of vancomycin from different patients were reviewed; 51 normal weight patients, 45 overweight patients and 18 obese patients, with a mean age of 61.27 ± 18.49, 68.46 ± 13.07 and 66.27 ± 13.47 years, respectively.In the normal weight group, 74.5% were men and 25.5% were women; in overweight group, 73.3% were men and 26.7% were women; and in obesity group, 66.6% were men and 33.3% were women.Mean (SD) plasma levels of vancomycin in the normal weight group were 13.98 ± 10.61 µg/mL, in the overweight group 13.77 ± 8.32 µg/mL and in the obese group 10.7 ± 4.67 µg/mL.In the statistical study, we obtained a value distribution F of 1.1669, less than 3.09, a value that should be overcome to have statistical significance (95%).ConclusionThe standard starting dose of 1 g/12 h reaches the therapeutic range in most patients. There was no statistically significant relationship between BMI and mean plasma levels of vancomycin in our study, possibly because of the small sample size.No conflict of interest.</description><subject>Antibiotics</subject><subject>Body mass index</subject><subject>Creatinine</subject><subject>Obesity</subject><subject>Overweight</subject><subject>Plasma</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtOwzAQRS0EElXpP1hinTJ-x0tU8RKV6ALWlpM4SqrGDnYKdMeGH-VLSCmwZDWjmaN7pYMQJjAnhMkLt276xsYuo0BkBgC5EnPOyBGaUOAq01ry479dyFM0S6ktQDCWa870BLnV_SoDmn--f6w2NnUWl8GXzg_RDm3wONTY4jRYX9lY4Soktz-9WF-Gble2Ho8fHN3mm05N2-PXdmhwEaod7mxKuPWVeztDJ7XdJDf7mVP0dH31uLjNlg83d4vLZVYQAJ054BV1kpVlrQuQjgiigFaUA9U1BaipUpYy0CXnvJAjkoMAQmsqi7wmjk3R-SG3j-F569Jg1mEb_VhpqBBUCaKJ_o8iKudCaKXZSLEDVXRr08e2s3FnCJi9ePMr3uzFm4N4M4pnX2Lsd24</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Llorca, A Marti</creator><creator>Mateos, A Andújar</creator><creator>Iranzo, E Garcia</creator><creator>Vozmediano, R Gutiérrez</creator><creator>Monsalve, A García</creator><creator>Ruiz, A Navarro</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>201603</creationdate><title>PKP-028 Plasma concentration of a standard dose of vancomycin and relationship with body mass index</title><author>Llorca, A Marti ; Mateos, A Andújar ; Iranzo, E Garcia ; Vozmediano, R Gutiérrez ; Monsalve, A García ; Ruiz, A Navarro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1009-e04d2e63ccf9b06e151702d24029f200f277a2309c444b6b06805012f26b8f1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antibiotics</topic><topic>Body mass index</topic><topic>Creatinine</topic><topic>Obesity</topic><topic>Overweight</topic><topic>Plasma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Llorca, A Marti</creatorcontrib><creatorcontrib>Mateos, A Andújar</creatorcontrib><creatorcontrib>Iranzo, E Garcia</creatorcontrib><creatorcontrib>Vozmediano, R Gutiérrez</creatorcontrib><creatorcontrib>Monsalve, A García</creatorcontrib><creatorcontrib>Ruiz, A Navarro</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Llorca, A Marti</au><au>Mateos, A Andújar</au><au>Iranzo, E Garcia</au><au>Vozmediano, R Gutiérrez</au><au>Monsalve, A García</au><au>Ruiz, A Navarro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PKP-028 Plasma concentration of a standard dose of vancomycin and relationship with body mass index</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2016-03</date><risdate>2016</risdate><volume>23</volume><issue>Suppl 1</issue><spage>A191</spage><epage>A191</epage><pages>A191-A191</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>PurposeThe objective of this study was to evaluate a standard starting dose of vancomycin and a possible relationship between body mass index (BMI) and plasma levels (therapeutic range 10–15 µg/mL).Material and methodsRetrospective study of samples collected in a tertiary hospital of 413 beds, over a period of 3 years (2012–2014), in patients who were prescribed a standard initial dose of vancomycin 1 g/12 h.Data collected were: weight, height, gender, age, creatinine plasma levels and vancomycin plasma levels. The collected data were grouped according to BMI (18.5–25=normal weight, 25–30=overweight and >30=obesity) and plasma concentrations of vancomycin. Exclusion criteria were: samples from patients with renal insufficiency (creatinine >1.2 mg/dL) and patients with an initial dose of vancomycin different from the standard dose.The relationship between plasma levels of vancomycin and BMI was assessed by ANOVA statistical analysis.Results114 determinations of plasma levels of vancomycin from different patients were reviewed; 51 normal weight patients, 45 overweight patients and 18 obese patients, with a mean age of 61.27 ± 18.49, 68.46 ± 13.07 and 66.27 ± 13.47 years, respectively.In the normal weight group, 74.5% were men and 25.5% were women; in overweight group, 73.3% were men and 26.7% were women; and in obesity group, 66.6% were men and 33.3% were women.Mean (SD) plasma levels of vancomycin in the normal weight group were 13.98 ± 10.61 µg/mL, in the overweight group 13.77 ± 8.32 µg/mL and in the obese group 10.7 ± 4.67 µg/mL.In the statistical study, we obtained a value distribution F of 1.1669, less than 3.09, a value that should be overcome to have statistical significance (95%).ConclusionThe standard starting dose of 1 g/12 h reaches the therapeutic range in most patients. There was no statistically significant relationship between BMI and mean plasma levels of vancomycin in our study, possibly because of the small sample size.No conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2016-000875.431</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A191-A191 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_proquest_journals_2552751919 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Antibiotics Body mass index Creatinine Obesity Overweight Plasma |
title | PKP-028 Plasma concentration of a standard dose of vancomycin and relationship with body mass index |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T08%3A49%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PKP-028%E2%80%85Plasma%20concentration%20of%20a%20standard%20dose%20of%20vancomycin%20and%20relationship%20with%20body%20mass%20index&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Llorca,%20A%20Marti&rft.date=2016-03&rft.volume=23&rft.issue=Suppl%201&rft.spage=A191&rft.epage=A191&rft.pages=A191-A191&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2016-000875.431&rft_dat=%3Cproquest_bmj_p%3E2552751919%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784559793&rft_id=info:pmid/&rfr_iscdi=true |